The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With CTC Clinical Trial Consultants AB, Karolinska Institutet.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
8actual
Sites
1
Country
Sweden
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-26 | actual | When the study began enrolling |
| Primary completion | 2026-07-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-02 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Liver Fibrosis
- Hepatic Cirrhosis
Interventions
- Drug: AZD2389
- Diagnostic test: PET scan and radioligand — also filed as The participants will perform the PET examination at the PET Centre using the radioligand [68Ga]Ga-FAPI-46.
Primary outcome
what the primary-completion date above is the date OFOccupancy, %: percent change from baseline in uptake of FAP PET radioligand [68Ga]Ga-FAPI-46 in the liver after a single dose of AZD2389.
measured PART B: Day 7(+/-2 days); PART C: Day 2 and Day 8 (+/-2 days)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed